USP17L8: A Potential Drug Target and Biomarker for Ubiquitin-Specific Peptidase 17-Like Family Member 8
USP17L8: A Potential Drug Target and Biomarker for Ubiquitin-Specific Peptidase 17-Like Family Member 8
Ubiquitin-specific peptidase 17 like family member 8 (USP17L8) is a member of the ubiquitin-specific peptidase family 17, which plays a crucial role in the regulation of protein stability and degradation.USP17L8 has been identified as a potential drug target and biomarker due to its unique structure and function. In this article, we will discuss the biology and potential drug targets of USP17L8.
Structure and Function
The ubiquitin system is a protein degradation pathway that is essential for the regulation of protein stability and function. Ubiquitin is a large protein that plays a central role in this system by forming a covalent complex with target proteins. This covalent complex is then targeted for degradation by the 26S proteasome, which is a complex of enzymes that break down proteins into smaller peptides.
USP17L8 is a member of the ubiquitin-specific peptidase family 17, which includes a variety of enzymes that share a similar catalytic mechanism but differ in their specificity for different ubiquitin epitopes.USP17L8 has a unique structure that consists of a catalytic core and a distinct N-terminal region that is responsible for its specificity for the ubiquitin epitope specific for USP17L6.
USP17L8 functions as a ubiquitin-specific peptidase by cleaving the N-terminus of the target protein with its specificity for the USP17L6 epitope. This cleavage leads to the formation of a covalent complex between USP17L8 and the target protein, which can then be targeted for degradation by the 26S proteasome.
Potential Drug Targets
The USP17L8 enzyme has been identified as a potential drug target due to its unique structure and function. Several studies have shown that inhibition of USP17L8 can significantly reduce the levels of target proteins in cell culture and animal models of disease.
One of the potential drug targets for USP17L8 is its role in cancer progression.USP17L8 has been shown to be involved in the regulation of cell cycle progression and has been associated with the development of several types of cancer. inhibition of USP17L8 has been shown to inhibit the growth and survival of cancer cells.
Another potential drug target for USP17L8 is its role in neurodegenerative diseases.USP17L8 has been shown to be involved in the regulation of neurotrophic factor (NTF) levels, which are important for the maintenance of neural function. inhibition of USP17L8 has been shown to reduce NTF levels and improve neural function in animal models of neurodegenerative diseases.
Potential Biomarkers
USP17L8 has also been identified as a potential biomarker for several types of disease. The levels of USP17L8 have been shown to be elevated in several types of disease, including cancer, neurodegenerative diseases, and autoimmune diseases.
In addition, the activity of USP17L8 has been shown to be affected by several factors, including pH, temperature, and inhibitors. Therefore, USP17L8 could be used as a biomarker for monitoring the effectiveness of different treatments.
Conclusion
In conclusion, USP17L8 is a unique enzyme that plays a crucial role in the regulation of protein stability and degradation. Its unique structure and function make it a potential drug target and biomarker for several types of disease. Further research is needed to fully understand the role of USP17L8 in
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 8
The "USP17L8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L8 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2
